Dimethyl Fumarate
Treatment for Multiple Sclerosis
Typical Dosage: 120mg oral twice daily for 7 days, then 240mg oral twice daily
Effectiveness
82%
Safety Score
42%
Clinical Trials
103
Participants
2.6K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
42
DangerousModerateSafe
Treatment Details
Dosage Range
120mg oral twice daily for 7 days, then 240mg oral twice daily
Time to Effect
2-3 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$85,000
Monitoring:$4,000
Side Effect Mgmt:$500
Total Annual:$89,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$114,743.59
Cost per Remission
$298,333.33
Comparison vs Interferon Beta-1a
Cost Difference
+$24,500/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Dimethyl Fumarate Outcomes
for Multiple Sclerosis
Efficacy Outcomes
Overall Effectiveness
+82%
Response Rate
+78%
Remission Rate
+30%
Common Side Effects
Flushing
+40%
Abdominal pain
+18%
Diarrhea
+14%
Nausea
+12%
Lymphopenia (Grade 3/4)
+2%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
12 completed trials for Dimethyl Fumarate in Multiple Sclerosis
A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
NCT05658484COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Beijing, China +14 more
Started: Jun 9, 2023
Dimethyl Fumarate (DMF) Observational Study
NCT02047097COMPLETED
5.49K participants
OBSERVATIONAL
Birmingham, United States +467 more
Started: Nov 19, 2013
Study of Utilization Patterns of Dimethyl Fumarate in Germany
NCT02969304COMPLETED
930 participants
OBSERVATIONAL
Leipzig, Germany
Started: Dec 30, 2016
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
NCT02525874COMPLETEDPHASE3
218 participants
INTERVENTIONAL
Gilbert, United States +33 more
Started: Aug 11, 2015
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
NCT01930708COMPLETEDPHASE4
1.11K participants
INTERVENTIONAL
Innsbruck, Austria +89 more
Started: Oct 31, 2013
Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
NCT02461069COMPLETEDPHASE4
67 participants
INTERVENTIONAL
Bonn, Germany +5 more
Started: May 6, 2015
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
NCT01156311COMPLETEDPHASE2
108 participants
INTERVENTIONAL
Gilbert, United States +15 more
Started: Jun 1, 2010
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
NCT02125604COMPLETEDPHASE4
214 participants
INTERVENTIONAL
Augsburg, Germany +18 more
Started: Jun 1, 2014
Tecfidera Lymphocyte Chart Review
NCT02519413COMPLETED
483 participants
OBSERVATIONAL
Homewood, United States +9 more
Started: Jul 1, 2015
Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera
NCT04756687COMPLETED
1.51K participants
OBSERVATIONAL
Amiens, France +31 more
Started: Mar 10, 2021
Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
NCT02739542COMPLETEDPHASE4
87 participants
INTERVENTIONAL
Los Angeles, United States +10 more
Started: Mar 19, 2016
Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers
NCT04022473COMPLETEDPHASE1
210 participants
INTERVENTIONAL
Columbia, United States
Started: Jul 7, 2019
Showing 20 of 104 total trials